Molecular insights into ago-allosteric modulation of the human glucagon-like peptide-1 receptor

Z Cong, LN Chen, H Ma, Q Zhou, X Zou, C Ye… - Nature …, 2021 - nature.com
Z Cong, LN Chen, H Ma, Q Zhou, X Zou, C Ye, A Dai, Q Liu, W Huang, X Sun, X Wang, P Xu
Nature communications, 2021nature.com
Abstract The glucagon-like peptide-1 (GLP-1) receptor is a validated drug target for
metabolic disorders. Ago-allosteric modulators are capable of acting both as agonists on
their own and as efficacy enhancers of orthosteric ligands. However, the molecular details of
ago-allosterism remain elusive. Here, we report three cryo-electron microscopy structures of
GLP-1R bound to (i) compound 2 (an ago-allosteric modulator);(ii) compound 2 and GLP-1;
and (iii) compound 2 and LY3502970 (a small molecule agonist), all in complex with …
Abstract
The glucagon-like peptide-1 (GLP-1) receptor is a validated drug target for metabolic disorders. Ago-allosteric modulators are capable of acting both as agonists on their own and as efficacy enhancers of orthosteric ligands. However, the molecular details of ago-allosterism remain elusive. Here, we report three cryo-electron microscopy structures of GLP-1R bound to (i) compound 2 (an ago-allosteric modulator); (ii) compound 2 and GLP-1; and (iii) compound 2 and LY3502970 (a small molecule agonist), all in complex with heterotrimeric Gs. The structures reveal that compound 2 is covalently bonded to C347 at the cytoplasmic end of TM6 and triggers its outward movement in cooperation with the ECD whose N terminus penetrates into the GLP-1 binding site. This allows compound 2 to execute positive allosteric modulation through enhancement of both agonist binding and G protein coupling. Our findings offer insights into the structural basis of ago-allosterism at GLP-1R and may aid the design of better therapeutics.
nature.com
以上显示的是最相近的搜索结果。 查看全部搜索结果